Merck & Co Inc
JPMorgan’s top biotech and pharma picks for the second half
Biopharmaceutical stocks’ underperformance versus the broader market for a third-straight year is an opportunity for investors, according to JPMorgan. Analyst Chris Schott said in the firm’s June outlook for biopharma that the sector’s poor performance can be traced back to concerns over President Donald Trump’s tariffs and his ” most favored nation ” executive order. […]
Read More
Healthy Returns: AstraZeneca, Pfizer, Gilead and other drugmakers release promising cancer drug data at ASCO
Attendees walk through the lobby at the American Society of Clinical Oncology annual meeting in Chicago. Tim Boyle | Bloomberg | Getty Images A version of this article first appeared in CNBC’s Healthy Returns newsletter, which brings the latest health-care news straight to your inbox. Subscribe here to receive future editions. I’m back in New […]
Read More
Healthy Returns: Trump provides a glimpse of the third round of Medicare drug price negotiations
In a photo illustration, prescription drugs are seen next to a pill bottle on July 23, 2024 in New York City. Spencer Platt | Getty Images News | Getty Images A version of this article first appeared in CNBC’s Healthy Returns newsletter, which brings the latest health-care news straight to your inbox. Subscribe here to […]
Read More
Trump’s plan to slash drug prices may struggle to get off the ground – here’s what to know
President Donald Trump, joined by National Institutes of Health (NIH) Director Jay Bhattacharya, speaks during a press conference in the Roosevelt Room of the White House on May 12, 2025, in Washington, DC. Andrew Harnik | Getty Images News | Getty Images President Donald Trump on Monday moved forward with a plan to lower U.S. […]
Read More
Stocks making the biggest moves midday: Amazon, Alibaba, Merck, Five Below, Nike and more
Check out the companies making headlines in midday trading: Drugmakers — Pharmaceutical stocks bounced back from earlier losses after an executive order aimed at bringing down drug prices was deemed not as bad as feared for the industry. Merck jumped 5%, while Pfizer , Bristol-Myers Squibb and Eli Lilly all rose more than 2%. However, […]
Read More
Trump to sign order to cut some U.S. drug prices to match lower ones abroad
President Donald Trump on Monday will revive a controversial policy that aims to slash drug costs by tying the amount the government pays for some medicines to lower prices abroad, White House officials said. Trump will sign an executive order including several different actions to renew that effort, known as the “most favored nation” policy. […]
Read More
Stocks making the biggest moves premarket: Nvidia, Best Buy, Eli Lilly, Tesla, Amazon and more
Check out the companies making headlines before the bell. Big Tech stocks – Shares of megacap technology companies surged after the U.S. and China agreed to temporarily cut tariffs , bringing the U.S. tariff rate on Chinese imports down to 30% and China’s duties on U.S. imports to 10%. Tesla , which has seen declining […]
Read More
Inside the deal: Roche and Zealand Pharma’s $5.3 billion obesity drug gambit
A view of the sign and logo of the Roche Holding AG headquarters on April 11, 2025 in Basel, Switzerland. Sedat Suna | Getty Images News | Getty Images COPENHAGEN, Denmark — The ballooning obesity drug market may have a new contender after Roche struck a $5.3 billion deal to develop Danish biotech Zealand Pharma’s “next generation” […]
Read More
Healthy Returns: Here are the drugmakers with new U.S. investments as Trump’s pharma tariffs loom
Jgi/jamie Grill | Tetra Images | Getty Images A version of this article first appeared in CNBC’s Healthy Returns newsletter, which brings the latest health-care news straight to your inbox. Subscribe here to receive future editions. Tariff threats — and efforts to get into President Donald Trump’s good graces — are fueling a new wave […]
Read More
Why we’re lowering our Bristol Myers price target despite an earnings beat, guidance raise
Bristol Myers Squibb ‘s earnings beat and rosy outlook Thursday did not resolve lingering issues for the stock. But it was enough, for now. Revenue in the first quarter, which ended March 31, dipped 6% to $11.2 billion but topped estimates of $10.7 billion, according to LSEG. Adjusted earnings per share of $1.80 beat expectations […]
Read More